KAYS (Kaya Holdings) Tariff Resilience Score: 7/10 (As of Jul. 06, 2026)


What is Kaya Holdings Tariff Resilience Score?

Kaya Holdings KAYS Tariff Resilience Score is 7 as of Jul. 06, 2026. The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Kaya Holdings ranks better than 97.09% on this metric.

Kaya Holdings has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Kaya Holdings has Relatively resilient due to domestic focus and limited international trade. Some exposure through imported materials, but strong local market presence and pricing power mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Kaya Holdings might have Highly Resilient.

Kaya Holdings  (OTCPK:KAYS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Kaya Holdings Tariff Resilience Score Related Terms

KAYS vs APUS, IGPK, BIOE: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kaya Holdings's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kaya Holdings Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaya Holdings's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Kaya Holdings's Tariff Resilience Score falls into.


What does a Tariff Resilience Score of 7 mean?
Kaya Holdings (KAYS) has a Tariff Resilience Score of 7 as of Jul. 06, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Kaya Holdings ranks #30 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Kaya Holdings' Tariff Resilience Score too high?
Kaya Holdings' current Tariff Resilience Score is 7. Based on the distribution chart, Kaya Holdings ranks #30 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Kaya Holdings' Tariff Resilience Score compare to APUS and IGPK?
According to the Drug Manufacturers industry distribution chart, Kaya Holdings ranks #30 out of 1030 companies for Tariff Resilience Score. This places Kaya Holdings in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Kaya Holdings's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaya Holdings stock overvalued right now?
Kaya Holdings (KAYS) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Kaya Holdings (KAYS), the current Tariff Resilience Score is 7 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaya Holdings Business Description

Address 21218 St. Andrews Boulevard, Suite 300, Boca Raton, FL, USA, 33433
Kaya Holdings Inc is a holding company. It is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products. The company own and operate a medical cannabis dispensary in the United States. Its has produced, distributed, and/or sold a full range of premium cannabis products including flower, oils, vape cartridges and cannabis infused confections, baked goods and beverages through a fully integrated group of subsidiaries and companies supporting distinctive brands.